Entries by akiibdh

AM-Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia

The orphan designations secure recAP position in rare disease area Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for […]

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Option may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase Bunnik, The Netherlands, and New York, NY – 11 May 2015 – AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP ) for inflammatory diseases, and Pfizer Inc. (NYSE: PFE) announced […]

AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

Bunnik, The Netherlands, 20 January 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory diseases, has recruited the first 3 patients into its Phase II trial of recAP in sepsis-associated Acute Kidney Injury (AKI). The clinical trial is now underway in 9 countries, and will involve […]

Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

recAP shown to improve skeletal and dental mineralisation in potentially new indication with high unmet medical need. Bunnik, The Netherlands, 2 December 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today announces that preclinical data on its drug candidate recAP, to treat the ultra […]

AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury

Data shows recAP to increase glomerular filtration rate and creatine clearance Bunnik, The Netherlands, 13 November 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents further preclinical data on its drug candidate recAP, at the American Society of Nephrology (ASN) meeting Kidney Week […]

AM-Pharma closes €12.2m financing round

New capital to complete Phase II development of recAP in Acute Kidney Injury Bunnik, The Netherlands, 11 September 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors AbbVie, BB […]

AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury

Bunnik, The Netherlands, 26 March 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses. In total 50 healthy […]

American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

Leading journal presents case for AM-Pharma product to treat sepsis-associated acute kidney injury. Bunnik, The Netherlands, 28 January 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that the American Journal of Kidney Disease has published an In Translation feature entitled: Alkaline phosphatase: a […]